REFERENCES
- Chabner B.A., Myers C.E. Clinical Pharmacology of Cancer Chemotherapy. Cancer: Principles and Practice of Oncology, 3rd Ed., V.T. De Vita, S. Hellman, S.A. Rosenberg. JB Lippincott Company, Philadelphia 1989; 349–395
- Lesesne J.B., Rothschild N., Erickson B., Korec S., Sisk R., Kellar J., Arbus M., Woolley P.V., Chiazze L., Schein P.S., Messerschmidt G.L. Cancer Associated Hemolytic Uremic Syndrome: Analysis of 85 Cases from a National Registry. J. Clin. Oncol. 1989; 7: 781–789
- Verwey J., Vries J.D., Pinedo H.M. Mitomycin C Induced Renal Toxicity, A Dose Dependent Side Effect?. Eur. J. Cancer Clin. Oncol. 1987; 23: 195–198
- Jain S., Seymour A.E. Mitomycin C Associated Hemolytic Uremic Syndrome. Pathology 1987; 19: 58–61
- Snyder H.W., Mittelman A., Oral A., Henry D.H., Korec S., Bertram J.H., Guthrie T.H., Jr., Ciavarella D., Wuest D. Treatment of Cancer Chemotherapy-Associated Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome by Protein A Immunoadsorption of Plasma. Cancer 1993; 71: 1882–1892
- Garibotto G., Acquarone N., Saffioti S., Deferrari G., Villagio B., Ferrario F. Successful Treatment of Mitomycin C Associated Hemolytic Uremic Syndrome by Plasmapheresis. Nephron 1989; 51: 409–412
- Chow S., Roscoe J., Cattran D.C. Plasmapheresis and Antiplatelet Agents in the Treatment of the Hemolytic Uremic Syndrome Secondary to Mitomycin. Am. J. Kid. Disease 1986; 7: 407–412